Novo Nordisk Has Plans For Semaglutide In NASH Too

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.

novo nordisk
Novo Nordisk's plans in NASH include semaglutide and several other candidates/combos • Source: Shutterstock: Tada Images

Non-alcoholic steatohepatitis is not the primary therapeutic focus at Novo Nordisk A/S, unlike companies such as Madrigal Pharmaceuticals, Inc., 89bio, Inc. or Inventiva S.A., but as an established powerhouse in diabetes and an emerging force in cardiometabolic disease it is a company worth paying attention to. The company has been keeping its ambitions in NASH close to the vest, but Novo Nordisk senior global medical director Jeppe Zacho offered Scrip some details at the American Association for the Study of Liver Disease annual meeting.

[Sidebar#SC149295]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.